• Net Product Sales: $71.3 million for Ohtuvayre in Q1 2025.
• Total Net Revenue: $76.3 million for Q1 2025.
• Cost of Sales: $3.4 million for Ohtuvayre in Q1 2025.
• Research and Development Expenses: $14.1 million in Q1 2025.
• Selling, General and Administrative Expenses: $69.1 million in Q1 2025.
• Operating Loss: $10.3 million for Q1 2025.
• Net Loss After Tax: $16.3 million for Q1 2025.
• Adjusted Net Income: $20.5 million for Q1 2025, excluding $36.8 million in share-based compensation.
• Cash and Equivalents: $401.4 million as of March 31, 2025.
• Debt Facility: $250 million outstanding with $200 million available for future draws.

• Warning! GuruFocus has detected 8 Warning Signs with VRNA.

Release Date: April 29, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Verona Pharma PLC (NASDAQ:VRNA) reported its first quarter 2025 revenue exceeded operating expenses, excluding non-cash charges, marking a significant financial milestone.
• The US launch of Ohtuvayre for COPD treatment has been highly successful, with sales nearly doubling from the previous quarter, reaching $71.3 million.
• Ohtuvayre has seen rapid adoption, with approximately 25,000 prescriptions filled in Q1 2025 and a 25% increase in new patient starts compared to Q4 2024.
• The company has expanded its prescriber base significantly, with total prescribers growing by about 50% relative to Q4 2024.
• Verona Pharma PLC (NASDAQ:VRNA) maintains a strong financial position with $401.4 million in cash and equivalents as of March 31, 2025, and an amended debt facility providing additional financial flexibility.

Negative Points

• Despite strong sales, Verona Pharma PLC (NASDAQ:VRNA) reported an operating loss of $10.3 million and a net loss after tax of $16.3 million for Q1 2025.
• The company faces uncertainties and risks associated with forward-looking statements, which could impact future performance.
• Research and development expenses increased to $14.1 million, reflecting higher costs related to clinical trials and share-based compensation.
• Selling, general, and administrative expenses were high at $69.1 million, driven by commercialization efforts for Ohtuvayre.
• The company is still in the early stages of its product launch, and while growth is promising, it remains to be seen if this momentum can be sustained long-term.

Q & A Highlights

Q: As we exit Q1 and enter Q2, can you talk about the trends that you're seeing? Can you share any color or characterize how healthy these metrics are looking in April so far and how might they look in May and June? A: David Zaccardelli, CEO: The launch is going extremely well, with high adoption and expansion across all metrics, including prescriptions, new prescribers, new patients, and refills. We are very encouraged by the persistency and expect the growth trajectory to continue.

Q: Do you think sales could inflect even faster in Q2, Q3, Q4? How are you envisioning the sales curve to look, whether it's more parabolic or linear from here? A: David Zaccardelli, CEO: We are extremely encouraged by the growth trajectory. The launch curve will shape chronically as a refill business, with new patient ads building the foundation. We expect substantial growth as there are millions of patients who remain symptomatic on the current standard of care.

Q: Can you provide any more color on the refill rate for patients who initiated Ohtuvayre treatment six or more months ago? A: Christopher Martin, Chief Commercial Officer: We are very encouraged by the persistency and refill rates since launch. While the number of patients eligible for multiple refills is smaller, the early data is promising, and we expect potential upside in persistency over time.

Q: Are you completely outside of the Medicare Part D redesign, or is that something that you also have to think about? A: Christopher Martin, Chief Commercial Officer: We are primarily reimbursed through medical benefits, either through traditional Part B or Medicare Advantage, and are not significantly affected by the Medicare Part D redesign.

Q: Can you elaborate on the potential for in-licensing or acquiring additional products? A: David Zaccardelli, CEO: We aim to grow the business by acquiring assets that leverage our capabilities in development, regulatory, and commercial, primarily in the respiratory space. We are looking at mid and later-stage products that complement our current portfolio.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.